vTv Therapeutics (NASDAQ:VTVT) Stock Rating Lowered by Zacks Research

vTv Therapeutics (NASDAQ:VTVT) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other research analysts have also issued reports on VTVT. Evercore began coverage on shares of vTv Therapeutics in a research note on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price target for the company. Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Finally, BTIG Research restated a “buy” rating and set a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Price Performance

Shares of vTv Therapeutics stock opened at $32.76 on Thursday. The company has a 50-day moving average of $34.70 and a 200 day moving average of $35.04. The firm has a market cap of $129.07 million, a price-to-earnings ratio of -35.23 and a beta of 0.27. vTv Therapeutics has a 1 year low of $14.00 and a 1 year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44. The business had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. On average, equities analysts anticipate that vTv Therapeutics will post -2.19 EPS for the current year.

Institutional Trading of vTv Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics during the fourth quarter valued at approximately $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the fourth quarter valued at approximately $731,000. Geode Capital Management LLC increased its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the last quarter. Finally, Baker BROS. Advisors LP increased its holdings in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the last quarter. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.